首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1738750

非何傑金氏淋巴瘤和慢性淋巴瘤治療市場（按治療類型、療法和地區分類），2026 年至 2032 年

Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Market By Treatment Type (Chemotherapy, Immunotherapy), Therapy (First-Line Therapy, Second-line Therapy), & Region for 2026-2032

出版日期: 2025年05月05日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

非何傑金氏淋巴瘤與慢性淋巴瘤治療市場評估（2026-2032 年）

全球非何傑金氏淋巴瘤淋巴瘤和慢性淋巴瘤發病率的上升極大地推動了對有效治療方案的需求，並推動了非何傑金氏淋巴瘤和慢性淋巴瘤治療方案的採用。包括單株抗體和嵌合抗原受體-T細胞療法在內的標靶治療的創新，正在推動市場規模在2024年突破92.6億美元，到2032年估值將達到約177.9億美元。

此外，診斷技術的進步使得人們能夠更早、更準確地檢測出這些淋巴瘤，從而刺激了非何傑金氏淋巴瘤和慢性淋巴瘤治療方法的採用。政府對癌症研究的資助增加和有利的報銷政策將推動市場在 2026 年至 2032 年期間以 8.5% 的複合年成長率成長。

非何傑金氏淋巴瘤和慢性淋巴瘤治療市場評估（2026-2032）

全球非何傑金氏淋巴瘤淋巴瘤和慢性淋巴瘤發病率的上升，大大推動了對有效治療方案的需求，並促進了非何傑金氏淋巴瘤和慢性淋巴瘤治療方案的推廣應用。包括單株抗體和嵌合抗原受體-T細胞療法在內的標靶治療的創新，正在推動市場規模在2024年突破92.6億美元，到2032年估值將達到約177.9億美元。

此外，診斷技術的進步使得人們能夠更早、更準確地檢測出這些淋巴瘤，從而刺激了非何傑金氏淋巴瘤和慢性淋巴瘤治療方法的採用。政府對癌症研究的津貼和優惠的報銷政策將推動市場在 2026 年至 2032 年期間以 8.5% 的複合年成長率成長。

標靶治療和免疫治療的進步將如何增加非何傑金氏淋巴瘤和慢性淋巴瘤的治療？

發生率的上升是非非何傑金氏淋巴瘤(NHL) 和慢性淋巴性白血病(CLL) 治療市場的主要驅動力。根據美國癌症協會的數據，預計2024年美國將新增80,470例NHL病例。《柳葉刀血液學》雜誌發表的一項研究報告顯示，1990年至2017年間，全球NHL發生率增加了約45%。患者數量的成長正刺激對新型治療方法研發的投資增加。

標靶治療和免疫治療的進展徹底改變了治療方法。 FDA核准Yescarta 和 Kymriah 等 CAR-T 細胞療法用於治療某些類型的非何傑金氏淋巴瘤，為抗治療性途徑。 2024 年 2 月，羅氏公司宣布了 III 期 POLARIX 試驗的積極結果，表明 PolyVe 和 R-CHP聯合治療與標準療法相比，顯著改善了未經治療的瀰漫大 B 細胞淋巴瘤患者的無惡化生存期。

全球人口老化是另一個關鍵的市場促進因素，因為非何傑金氏淋巴瘤和慢性淋巴性白血病的風險會隨著年齡的成長而增加。世界衛生組織預測，到2032年，全球六分之一的人口將達到60歲或以上。預計這一人口結構變化將增加對淋巴瘤治療的需求。此外，在基因組分析技術進步的支持下，個人化醫療方法的興起有望實現更個人化的治療策略，從而改善療效並推動市場成長。

網路安全以及非何傑金氏淋巴瘤和慢性淋巴瘤治療的費用是否會阻礙它們的採用？

在非何傑金氏淋巴瘤（NHL）和慢性淋巴性白血病（CLL）治療市場，CAR-T細胞療法、標靶治療和免疫療法等先進療法價格昂貴，尤其是在中低收入國家，儘管這些療法有效，但仍會限制許多患者獲得治療的機會，並阻礙這些創新療法的廣泛應用。

另一個主要阻礙因素是當前治療方法可能產生嚴重的副作用和併發症。化療和放射線治療雖然有效，但可能引起各種副作用，包括免疫抑制、疲勞和器官損傷。 CAR-T細胞療法和幹細胞移植等先進療法有嚴重併發症的風險，例如細胞激素釋放症候群和移植物抗宿主疾病。這些副作用可能會限制患者接受治療的合格和對治療計劃的依從性，從而影響整體治療效果。

獲得先進診斷工具和治療手段的有限性，尤其是在發展中地區，構成了重大挑戰。此外，患者和醫護人員對非何傑金氏淋巴瘤和慢性淋巴性白血病缺乏認知和了解，導致診斷延遲和治療不理想。在這些地區，醫療基礎設施薄弱、專業醫護人員短缺以及癌症治療資金不足進一步加劇了這一問題，使許多患者無法獲得及時有效的治療。

The rising incidence of NHL and CLL worldwide is significantly boosting the demand for effective treatment options is propelling the adoption of non-hodgkin's lymphoma and chronic lymphoma treatment. Innovations in targeted therapies, including monoclonal antibodies and CAR T-cell therapy is driving the market size surpass USD 9.26 Billion valued in 2024 to reach a valuation of around USD 17.79 Billion by 2032.

In addition to this, advances in diagnostic methods are enabling earlier and more accurate detection of these lymphomas is spurring up the adoption of non-hodgkin's lymphoma and chronic lymphoma treatment. Increased government funding for cancer research and favorable reimbursement policies are enabling the market to grow at a CAGR of 8.5% from 2026 to 2032.

Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Market Valuation - 2026-2032

How will Advancements in Targeted Therapies And Immunotherapies Increase Adoption of Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment?

Rising incidence rates are a key driver of the non-hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) treatment market. According to the American Cancer Society, an estimated 80,470 new cases of NHL were expected in the US in 2024. The global incidence of NHL increased by approximately 45% between 1990 and 2017, as reported in a study published in The Lancet Haematology. This growing patient population has spurred increased investment in research and development of novel therapies.

Advancements in targeted therapies and immunotherapies have revolutionized treatment approaches. The FDA approval of CAR T-cell therapies, such as Yescarta and Kymriah, for certain types of NHL has opened new avenues for treatment-resistant patients. In February 2024, Roche announced positive results from their phase III POLARIX study, showing that Polivy plus R-CHP significantly improved progression-free survival compared to the standard of care in previously untreated diffuse large B-cell lymphoma patients.

The aging global population is another significant market driver, as NHL and CLL risk increases with age. The World Health Organization projects that by 2032, 1 in 6 people in the world will be aged 60 years or over. This demographic shift is expected to increase the demand for lymphoma treatments. Additionally, the rise of personalized medicine approaches, supported by advancements in genomic profiling, is enabling more tailored treatment strategies, potentially improving outcomes and driving market growth.

Will Cybersecurity and Costs of Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Restrain Its Application?

The high cost of advanced therapies like CAR T-cell therapy, targeted therapies, and immunotherapies in the non-hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) treatment market, particularly in low- and middle-income countries, can limit access for many patients, despite their efficacy, and hinder widespread adoption of these innovative treatments.

Another significant restraint is the potential for severe side effects and complications associated with current treatment modalities. Chemotherapy and radiation therapy, while effective, can cause a range of adverse effects, including immune suppression, fatigue, and organ damage. Advanced therapies like CAR T-cell therapy and stem cell transplants carry risks of serious complications such as cytokine release syndrome and graft-versus-host disease. These side effects can limit patient eligibility and adherence to treatment plans, impacting overall treatment outcomes.

Limited access to advanced diagnostic tools and treatments, particularly in developing regions, poses a major challenge. There is also a lack of awareness and understanding about NHL and CLL among patients and healthcare providers, leading to delayed diagnoses and suboptimal treatment. Inadequate healthcare infrastructure, shortage of specialized medical professionals, and insufficient funding for cancer care in these regions further exacerbate the issue, preventing many patients from receiving timely and effective treatment.

Category-Wise Acumens

Will Rise in Adoption of Stem Cell Transplantation (SCT) Drive Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Market?

Stem Cell Transplantation (SCT) is emerging as a leading treatment option for non-hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). According to the Center for International Blood and Marrow Transplant Research, the number of autologous stem cell transplants for NHL increased by 35% between 2010 and 2020. The National Marrow Donor Program reported that as of 2024, approximately 22,000 allogeneic transplants are performed annually worldwide for various hematologic malignancies, including NHL and CLL. This growth is driven by improved transplant techniques, reduced complications, and expanded donor pools.

Advancements in SCT protocols have significantly improved outcomes. A study published in the New England Journal of Medicine in February 2024 demonstrated that CAR T-cell therapy followed by autologous SCT increased 3-year progression-free survival rates by 40% compared to standard chemotherapy in relapsed/refractory large B-cell lymphoma patients. In March 2024, Novartis announced promising results from their phase II ELARA trial, showing that Kymriah (tisagenlecleucel) followed by SCT achieved a complete response rate of 85% in follicular lymphoma patients.

The expanding use of haploidentical transplants has broadened SCT accessibility. The National Cancer Institute reported a 150% increase in haploidentical transplants for lymphoma between 2015 and 2024. In April 2024, Gamida Cell received FDA approval for Omisirge, a cell therapy product designed to enhance engraftment in patients undergoing allogeneic SCT. This approval is expected to further boost the adoption of SCT in NHL and CLL treatment, potentially increasing market growth by 15-20% over the next five years.

Which Factors Contributing to Palliative Care Segment's Dominance in Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Market?

Palliative care is becoming increasingly crucial in non-hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) treatment, significantly impacting market dynamics. According to the National Hospice and Palliative Care Organization, referrals for palliative care in hematologic malignancies increased by 40% between 2018 and 2024. A study published in the Journal of Clinical Oncology in January 2024 reported that early integration of palliative care in NHL treatment improved quality of life scores by 30% and reduced hospital readmissions by 25%. This growing recognition of palliative care's value has led to increased investment in specialized programs and services.

The expansion of home-based palliative care services has been a key market driver. The Centers for Medicare & Medicaid Services reported a 60% increase in reimbursements for home-based palliative care for NHL and CLL patients from 2020 to 2024. In March 2024, Amedisys, a leading home health care provider, announced a partnership with the Leukemia & Lymphoma Society to launch a nationwide home-based palliative care program specifically tailored for lymphoma patients. This initiative aims to improve access to specialized care and is projected to serve over 10,000 patients in its first year.

Technological advancements in symptom management have further propelled the palliative care market. The FDA's approval of novel pain management devices and medications specifically for cancer-related pain has expanded treatment options. In February 2024, Johnson & Johnson unveiled a new wearable device for continuous pain monitoring in lymphoma patients, which integrates with telehealth platforms for real-time palliative care interventions. Additionally, Pfizer announced positive results from a phase III trial of a new opioid formulation designed to minimize side effects in hematologic cancer patients, potentially improving the quality of life for those receiving palliative care.

Country/Region-wise Acumens

Will Strong Presence of Key Pharmaceutical Companies in North America Mature Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Market?

North America dominating the non-hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) treatment market, driven by high incidence rates and advanced healthcare infrastructure. According to the National Cancer Institute, an estimated 80,470 new cases of NHL were diagnosed in the United States in 2024, representing about 4% of all new cancer cases. The American Cancer Society reported that the 5-year relative survival rate for NHL has improved to 73% as of 2024, up from 69% in 2014. This improvement is largely attributed to the region's early adoption of innovative therapies and significant investment in research and development.

The United States dominates the North American market, bolstered by robust reimbursement policies and a strong presence of key pharmaceutical companies. The Centers for Medicare & Medicaid Services reported a 25% increase in spending on NHL and CLL treatments between 2020 and 2024. In February 2024, Gilead Sciences announced positive results from their phase III ZUMA-7 trial, demonstrating that CAR T-cell therapy Yescarta significantly improved event-free survival compared to standard of care in relapsed or refractory large B-cell lymphoma patients. This breakthrough is expected to further solidify North America's market leadership.

Canada is also contributing significantly to the region's dominance. Health Canada reported a 15% increase in approved clinical trials for NHL and CLL treatments from 2022 to 2024. In March 2024, Canadian biotech company BioVaxys Technology Corp. announced a partnership with the Princess Margaret Cancer Centre to develop a novel immunotherapy for follicular lymphoma. Additionally, the Canadian government's recent allocation of $500 million for cancer research over the next five years, announced in April 2024, is expected to further boost innovation in lymphoma treatments, potentially expanding North America's market share by an additional 3-5% by 2026.

Will Rising Advanced Therapies in Asia Pacific Drive the Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Market Growth?

The Asia Pacific region is experiencing rapid growth in the non-hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) treatment market, driven by increasing incidence rates and improving healthcare infrastructure. According to the World Health Organization, the incidence of NHL in Southeast Asia increased by 30% between 2015 and 2024. China's National Cancer Center reported a 25% rise in NHL cases from 2018 to 2024, with an estimated 88,090 new cases in 2024. This growing patient population, coupled with rising healthcare expenditure in countries like India and China, is fueling market expansion.

Improved access to advanced therapies is accelerating market growth. Japan's Pharmaceuticals and Medical Devices Agency approved 15 new treatments for NHL and CLL between 2020 and 2024, a 50% increase from the previous five-year period. In February 2024, BeiGene announced positive results from their phase III ALPINE study, showing that Brukinsa (zanubrutinib) demonstrated superior progression-free survival compared to ibrutinib in CLL patients. This development is expected to significantly impact the Asian market, potentially increasing BeiGene's market share by 10-15% over the next two years.

Competitive Landscape

The non-hodgkin's lymphoma and chronic lymphoma treatment market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the non-hodgkin's lymphoma and chronic lymphoma treatment market include:

Roche Holding AG
AbbVie, Inc.
Gilead Sciences, Inc.
Novartis International AG
Bristol-Myers Squibb Company
Amgen, Inc.
Johnson & Johnson
AstraZeneca PLC
Pfizer, Inc.
Celgene Corporation
Merck & Co., Inc.
Eli Lilly and Company
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Seagen, Inc.
Astellas Pharma, Inc.
Bayer AG
Incyte Corporation
Kite Pharma (a Gilead Company)
BeiGene, Ltd.

Latest Developments

In February 2024, BeiGene's Brukinsa (zanubrutinib) received FDA approval for the treatment of chronic lymphocytic leukemia, based on superior efficacy demonstrated in the ALPINE study compared to ibrutinib.
In May 2024, Gilead Sciences launched a global phase III trial evaluating a novel bispecific antibody, GS-3583, in combination with standard of care for previously untreated diffuse large B-cell lymphoma patients.